Vaxcyte, Inc.
825 Industrial Road, Suite 300
San Carlos
CA
94070
United States
Tel: (650) 837-0111
Website: https://vaxcyte.com/
Email: info@Vaxcyte.com
About Vaxcyte, Inc.
Vaxcyte, Inc. (Nasdaq: PCVX) is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent some of the most common and deadly infectious diseases worldwide. Our exclusively licensed cell-free protein synthesis platform and our proprietary know how enable us to design and produce optimized protein carriers and antigens, the critical building blocks of vaccines, in ways that we believe conventional vaccine technologies cannot. Our lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease. Our pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease.
97 articles about Vaxcyte, Inc.
-
Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2/10/2022
Vaxcyte, Inc. today announced that Company management will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 2:20 p.m. ET / 11:20 a.m. PT.
-
Vaxcyte Announces Pricing of $100 Million Public Offering
1/13/2022
Vaxcyte, Inc., a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced the pricing of an underwritten public offering of common stock and pre-funded warrants.
-
Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
1/12/2022
Vaxcyte, Inc. announced today that it has commenced an underwritten public offering of its common stock and pre-funded warrants.
-
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease
1/6/2022
Vaxcyte, Inc. (Nasdaq: PCVX), announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for VAX-24, its lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease.
-
Vaxcyte to Present at Upcoming Investor Conferences - Nov 11, 2021
11/11/2021
Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, announced that Company management will participate in and host one-on-one meetings at the following virtual investor conferences.
-
Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update
11/10/2021
Vaxcyte, Inc. today announced financial results for the third quarter ended September 30, 2021 and provided a business update.
-
Vaxcyte Appoints Carlos Paya and Michael Kamarck to Its Board of Directors
10/28/2021
Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced it has appointed Carlos Paya and Michael Kamarck, accomplished industry leaders, to its board of directors.
-
Vaxcyte to Present at Guggenheim 2nd Annual Vaccine and Infectious Disease Conference
9/28/2021
Vaxcyte, Inc. announced that Company management will participate in a fireside chat at the Guggenheim 2nd Annual Vaccine and Infectious Disease Conference on Tuesday, October 5, 2021 at 11:30am ET.
-
Vaxcyte to Present at 2021 Cantor Virtual Global Healthcare Conference
9/21/2021
Vaxcyte, Inc. today announced that Company management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 8:40am ET.
-
Vaxcyte Appoints Annie Drapeau and Teri Loxam to Its Board of Directors
9/20/2021
Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced it has appointed Annie Drapeau and Teri Loxam to its board of directors.
-
Vaxcyte Reports Second Quarter 2021 Financial Results and Provides Business Update
8/11/2021
Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.
-
Vaxcyte Announces Expanded CARB-X Award to Advance Development of VAX-A1, a Vaccine to Prevent Group A Streptococcus Infections
8/5/2021
Vaxcyte, Inc. today announced an additional award of $3.2 million from CARB-X to advance development of VAX-A1, a novel vaccine designed to prevent infections caused by Group A Streptococcus pyogenes (Strep) bacteria.
-
Vaxcyte to Present at the Jefferies Virtual Healthcare Conference
5/27/2021
Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that Company management will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 4:00pm ET.
-
Vaxcyte Announces Publication of Preclinical Data Supporting the Potential of VAX-24 for the Prevention of Invasive Pneumococcal DiseaseVAX-24 is a 24-Valent Broad-Spectrum Pneumococcal Conjugate Vaccine Leveraging Vaxcyte’s Technology Platform
5/10/2021
Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the publication of preclinical data supporting the potential of VAX-24, its lead vaccine candidate, in the journal Vaccine
-
Vaxcyte to Present at BofA Securities 2021 Health Care Conference
5/6/2021
Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, announced that Company management will present at the BofA Securities 2021 Health Care Conference on Thursday, May 13, 2021 at 3:30pm ET.
-
Vaxcyte to Present at 20th Annual Needham Virtual Healthcare Conference
4/5/2021
Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will participate in a fireside chat at the 20 th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 1:30 p.m. ET.
-
Vaxcyte Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
3/29/2021
Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update.
-
In a stunning fall from grace playing out this week, former Operation Warp Speed vaccine czar, Dr. Moncef Slaoui, issued a statement Thursday morning, as news emerged that he has resigned from additional biotech posts.
-
Vaxcyte to Report Fourth Quarter and Full Year 2020 Financial Results on March 29, 2021
3/22/2021
Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that it will report financial results for the fourth quarter and full year 2020 after market close on March 29, 2021
-
Vaxcyte Announces Publication of Preclinical Proof-of-Concept Data Supporting Potential of VAX-A1, a Novel Conjugate Vaccine Designed to Prevent Group A Strep Infections
1/6/2021
Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the publication of preclinical data for VAX-A1, the Company’s novel Group A Streptococcus (Group A Strep) conjugate vaccine candidate, in the journal Infectious Microbes & Diseases . Group A Strep is